Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Pediatric Genomic Medicine, |
RCV000435639 | SCV000511736 | uncertain significance | not provided | 2016-12-30 | criteria provided, single submitter | clinical testing | Converted during submission to Uncertain significance. |
Labcorp Genetics |
RCV000802922 | SCV000942771 | uncertain significance | Familial acute necrotizing encephalopathy | 2020-10-07 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C65"). This variant has not been reported in the literature in individuals with RANBP2-related disease. ClinVar contains an entry for this variant (Variation ID: 377321). This variant is present in population databases (rs377029115, ExAC 0.02%), and has an allele count higher than expected for a pathogenic variant (PMID: 28166811). This sequence change replaces proline with leucine at codon 512 of the RANBP2 protein (p.Pro512Leu). The proline residue is highly conserved and there is a moderate physicochemical difference between proline and leucine. |
Fulgent Genetics, |
RCV000802922 | SCV002782146 | uncertain significance | Familial acute necrotizing encephalopathy | 2021-11-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004022282 | SCV003865155 | uncertain significance | not specified | 2023-02-22 | criteria provided, single submitter | clinical testing | The c.1535C>T (p.P512L) alteration is located in exon 11 (coding exon 11) of the RANBP2 gene. This alteration results from a C to T substitution at nucleotide position 1535, causing the proline (P) at amino acid position 512 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |